# Precigen, Inc. (PGEN)

> Source: Nexqual · https://nexqual.com/PGEN · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Precigen, Inc. (PGEN), nexqual.com/PGEN" · informational, not investment advice.

**Price:** USD 7.2 (-2.18% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 7.36 · day 7.17–7.55 · 52w 3.04–8.98 · market cap $2.58B · NMS

## Key facts
- 1 of 80 tracked superinvestors hold PGEN (13F, Q2 2026): 0 new, 1 added, 0 reduced, 0 unchanged.
- Analysts: Buy (mean 2.00 on a 1–5 scale) (4 analysts), mean target USD 13.65 (range 11–17.95).
- Total return with dividends: 1Y +106.3% vs S&P 500 +18.1%; 5Y +54.7% vs S&P 500 +85.1%.
- Next earnings: 2026-11-12, EPS estimate USD 0.08, revenue estimate $72.3M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2025 | FY2025 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $14.3M | $26.9M | $6.2M | $3.9M | $9.7M | — |
| Operating income | — | — | -$99.8M | -$135M | -$111M | — |
| Net income | -$92.2M | $28.3M | -$95.9M | -$126M | -$251M | -$158M |
| EPS (diluted) | -$0.47 | $0.14 | -$0.39 | -$0.47 | -$1.37 | — |
| Free cash flow | -$63.0M | -$70.0M | -$68.5M | -$76.8M | -$89.8M | -$115M |
| Operating margin | — | — | -1602.5% | -3440.2% | -1141.1% | — |
| Net margin | -646.0% | 105.2% | -1540.6% | -3216.2% | -2588.2% | — |
| Revenue growth | -55.4% | +88.6% | -76.9% | -36.9% | +146.7% | — |
| Cash + short-term investments | $109M | $56.0M | $62.9M | $97.9M | $100M | — |
| Total debt | $180M | $43.2M | — | $0K | $93.2M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/B 59.1x · FCF yield -4.47% · Earnings yield -6.12% · Net debt $55.2M · EV $2.63B

## Superinvestors (SEC 13F-HR, Q2 2026)
1 of 80 tracked investors hold PGEN. Change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Samantha McLemore | Patient Capital Management | 3.61% | $109M | Added +6.8% |

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 4 analysts; mean target USD 13.65 (low 11, high 17.95).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-25 | B. Riley Securities | Initiated | Buy | $12 |
| 2026-08-05 | HC Wainwright & Co. | Target raised | Buy | $14 → $18 |
| 2026-08-03 | HC Wainwright & Co. | Reiterated | Buy | $14 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | +106.3% | +54.7% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +106.8% | +9.1% |
| Volatility (annualized) | 77.4% | 82.0% |
| Max drawdown | -40.5% (Feb 2026→Mar 2026) | -86.7% (Nov 2021→Dec 2024) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/PGEN · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt